Kay Yeung, MD PhD
Kay Yeung, MD, PhD, is a board-certified medical oncologist who specializes in the treatment of breast cancer. She uses numerous forms of therapy, including endocrine (anti-estrogen) therapy, chemotherapy, targeted therapy, and immunotherapy to offer the best possible treatment options.
Dr. Yeung is part of the Comprehensive Breast Health Center where she works with surgeons, radiation oncologists, and other specialists to provide patients with highly specialized care.
In addition to caring for her patients, Dr. Yeung is a physician-scientist whose research focuses on breast cancer, including understanding the mechanism of breast tumor dormancy and investigating clinical prognostic value of molecular profiling of circulating tumor cells. Her work has been published in Molecular Diagnosis & Therapy, Molecular Oncology, Clinical Cancer Research and Scientific Reports, and among others.
As an associate professor of medicine, she also teaches medical school students, residents, and fellows at UC San Diego School of Medicine. Dr. Yeung was chief fellow during her hematology/oncology fellowship at UC San Diego School of Medicine, where she also completed her residency in internal medicine.
She earned her medical degree and a doctorate in pharmacology at New York University School of Medicine. She is board certified in internal medicine and medical oncology.
Dr. Yeung is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Association for Cancer Research. She is a recipient of the Breast Cancer Research Program Breakthrough Fellowship Award from the Department of Defense.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:ArvinasDate added:07/17/2023Date updated:07/17/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:BiofluidicaDate added:07/17/2023Date updated:07/17/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:DantariDate added:07/17/2023Date updated:07/17/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:GileadDate added:07/17/2023Date updated:07/17/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:RegeneronDate added:07/17/2023Date updated:07/17/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:SeagenDate added:07/17/2023Date updated:07/17/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Jazz PharmaceuticalDate added:07/17/2023Date updated:07/17/2023